Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
Status:
Recruiting
Trial end date:
2022-10-17
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to characterize the effects of 2 oral doses (over 8 weeks total)
of CVL-231 on ambulatory blood pressure and heart rate in patients with stable schizophrenia.